{"name":"Collegium Pharmaceutical, Inc.","slug":"collegium","ticker":"COLL","exchange":"NASDAQ","domain":"collegiumpharma.com","description":"Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium ","hq":"Stoughton, Massachusetts","founded":2009,"employees":"423","ceo":"Michael Heffernan","sector":"Specialty Pharma","stockPrice":35.13,"stockChange":0.26,"stockChangePercent":0.75,"marketCap":"$1.1B","metrics":{"revenue":796329984,"revenueGrowth":8.9,"grossMargin":89.2,"rdSpend":0,"netIncome":62870000,"cash":421752992,"dividendYield":0,"peRatio":17.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Xtampza ER patent cliff ($143.1M at risk)","drug":"Xtampza ER","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"Tramadol ER patent cliff ($10.3M at risk)","drug":"Tramadol ER","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Oxycodone DETERx","genericName":"Oxycodone DETERx","slug":"oxycodone-deterx","indication":"Moderate to severe chronic pain requiring long-term opioid therapy","status":"phase_3"}]}],"pipeline":[{"name":"Oxycodone DETERx","genericName":"Oxycodone DETERx","slug":"oxycodone-deterx","phase":"phase_3","mechanism":"Oxycodone DETERx is an extended-release formulation of oxycodone, a mu-opioid receptor agonist, designed with abuse-deterrent technology to reduce the potential for misuse.","indications":["Moderate to severe chronic pain requiring long-term opioid therapy"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Collegium Pharmaceutical Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Collegium Pharmaceutical reported fourth quarter and full year 2023 financial results, with net sales of $143.1 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-09-14","type":"deal","headline":"Collegium Pharmaceutical Announces Agreement with Teva Pharmaceuticals to Settle Litigation","summary":"Collegium Pharmaceutical announced an agreement with Teva Pharmaceuticals to settle litigation related to Xtampza ER.","drugName":"","sentiment":"neutral"},{"date":"2023-06-15","type":"regulatory","headline":"FDA Approves Collegium Pharmaceutical's Xtampza ER for Pain Management","summary":"The FDA approved Collegium Pharmaceutical's Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE9NejkySEZTeFpxc3NqeDltLV9tX01IQTFTZmdIRFhLaEdheGZyYnYwN2EyZXZHVmlHTjItblJ0bEctb3k0aW0xYU1jR0YyalUzNHdYM3lpZGkxRGM?oc=5","date":"2026-04-04","type":"earnings","source":"Intellectia AI","summary":"COLL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI","headline":"COLL Financials: Revenue Breakdown, Margins & Competitor Comparison","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQSGNhTk5kMDNEWXNrYnYtLWI1NmowcGYwT2p1V2dQSThNTmYxdm5FdHduOXU3czNQRHRGNEtUdlVEUEQ3Nm13YTF2TlE4QmhON3IzNU9CeWkyUnY2ejBIZW5KV2lkZ0ZxLUltTVJ0WEZjNXZXYUlUV1Vmdlg4OEh6NmhENU9XRktTVWRzcVBCeS14Q3B0bXljSWVnQjljSlV4NVhLdGdpdldOSXZkYzREeEM5bEtiTzhYdTZ6cVBBQTVSZGNZZDJyU21SUEVrNmFNemYwOGZ1RkNTSkk0?oc=5","date":"2026-04-02","type":"pipeline","source":"StockStory","summary":"GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know - StockStory","headline":"GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOZ0J0VTEwM2Q0VERqVE5IdzVKYkFoYV9UcU0tTDNBNmpNamVMUkhTdUt2YUFYXy1WQXRjNXVBc0dyNW9DRFVEQWxRQlBwV2tKZVphMDIwRFhwekpDTkdZX0wtRG9vTjR1YVZIdF96WmxpZ2Z4NEJ3cGtuWE9XUVhlaWl3QnRTNTdpTHNoVFpYQlNRcUFKX1Z4dmN2dVZaQXM1R2ZEN1U0Uzhqa3Zz?oc=5","date":"2026-03-20","type":"pipeline","source":"Seeking Alpha","summary":"Collegium Pharmaceuticals: Another M&A Episode Adds To An Intriguing Case (NASDAQ:COLL) - Seeking Alpha","headline":"Collegium Pharmaceuticals: Another M&A Episode Adds To An Intriguing Case (NASDAQ:COLL)","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQTW0yM2l4VGQ3SFJLbUVzMmwyMV9VZDV1OWlkNVQyTExwajU5WHFpb1A0eUlYQkRIQ0lGQXZFOEVieFh1REpoZlN4TkdCZUNmU0hpTC1mYmFrQmFfT2lVdG1kV1FTNzZmSjFPQmp2ZzMyTUR3T1JpcGFRTXQ1dE5tU1FnYlMyS1ZfWWhrcWJkM1ltMzgwODNUWjFsdHpUd0E?oc=5","date":"2026-02-24","type":"earnings","source":"Finviz","summary":"Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy? - Finviz","headline":"Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-02","type":"earnings","source":"simplywall.st","summary":"What Collegium Pharmaceutical (COLL)'s Revenue Surge and Low Valuation Means For Shareholders - simplywall.st","headline":"What Collegium Pharmaceutical (COLL)'s Revenue Surge and Low Valuation Means For Shareholders","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPWWktUDl5c3B5aHRfSXlvZEJJR3lmRXpSbVduNlVZZlZoZjBoV2wwSGVrSF9xY2YtVnpRd3hXQzZ4eUcxWEVodDlBSml3MW1jcHVzV3ZsMTRDUGcyX2hIeERyMGFTNFhYLXJBZ2diekp5dEgyV2VHUmNSUlV4andTVzE3VEJOMVVJdi1mWFQzaFNrZ1BBSnpmZUZiSGFWbk5leTlKZQ?oc=5","date":"2026-01-21","type":"deal","source":"Seeking Alpha","summary":"Collegium Pharmaceutical: Buying The Projected Growth For 2026 - Seeking Alpha","headline":"Collegium Pharmaceutical: Buying The Projected Growth For 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxQNmk3WlJoYjdzRTBJeXBNOGRyaF9mdC1tMUgwc0wwVVF4QjFrT3h4X19CX25xQU1ycFE0MTFuLXpuR0NOWXExOXdVT3BKanRVRy1sX3oxcHI0R1VaUGo2dnpLcV9lcW5PcVVWa0JjdllJbk1zLTNDdGljamp3MkhJRkIwaldBMFFoXzEtYm5VV0JmYi04Zkt5aWVoLWRGT2tHWHVKUGl3Y3VMUnNELXY3b0tCRm5QLXVPSXF3dFpzekNqOVBKRzVvSlNCYmV5MDZld2FpbjdVOURvbGNCclVhVVNrQUJFZWFHTWFTVkQyNnTSAfYBQVVfeXFMTzZSeGxKcTlIRTZ1TWZVcFZkWU9hbUZpVzhtWGxxV3dsREU5Z1lSbmVzSV9QQ1E4LWRmZUxpcy1JOVF2MlRVancwQUo3ZUlIRFY4a1REaUFXak01SUhQX2NQY0VUSllkMDNXakdZWTF6cXF6Tk0tQ1VQLUZESTUwWjhHYlFSZl9xREhtR2JDa3dndkcxS0d3ZUlGS01BQkNlaGExYlNIekoxbmFOdVB1LXpESGZKTE1IMmdVTVF4UkxhQ1lyVFhJeHZ1YndNTlFnMkw1Y0k0ZnZiRkhQZVJzeDNiS1pmYjNYMDl6ZGtDdkRuTXlzMjZR?oc=5","date":"2025-10-19","type":"pipeline","source":"simplywall.st","summary":"We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt - simplywall.st","headline":"We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPb2o4S3FueFNlMld2S1IyWmlsaThVWGs4M1lISEpMSjBzTEJTWFE0SW5LcElzU29fUk5zeXdyZHNKSW5fVjllbmphN3gxeFFqTFM2aVhxV1BnRjY4Sm1MbEw3N3ZzYWVpak1JUWNPYVJWajlmMVpCN1B4YkNXMXNuRTBjLV9VanFldWhNZQ?oc=5","date":"2025-10-08","type":"pipeline","source":"Yahoo Finance","summary":"Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory - Yahoo Finance","headline":"Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-10","type":"pipeline","source":"simplywall.st","summary":"Is Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE Of 19% Impressive? - simplywall.st","headline":"Is Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE Of 19% Impressive?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPRDQtT0VIZ2FOOXVSTlR2RVRTdllBQlRuN3JMYzktMXdvb2FCZ0pzNW1GT3kwczczaU1MTTVKLXp5dmRhXzlsRnRtdExmSkFMUkJlQ0xaT21jZDhYU3plR1hmRHRDU2tUUUJjYVdoVl9Tb0ZXbFBRQVNDREZuNHFscFlwVlBySnZ5OHRTMDlfbDBTdkNfdk1DaEplaWxScmVnMEhGVmdsN0Q3MmxkcFctWF9TTDVBQU1hMDZKay1DUjd3VEtabDZsY0tRZGw?oc=5","date":"2025-07-07","type":"pipeline","source":"GlobeNewswire","summary":"Collegium Announces $150 Million Share Repurchase Program - GlobeNewswire","headline":"Collegium Announces $150 Million Share Repurchase Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPS0xZQnRhR2NhRFk3N3hjSGFoWTUzbGEybkM2QWs2Y3FQUThEVi1lNWRxNHV2TkZ0RXFVZkttS2JGd2tseW1UaXgwLXBxQ1dNcVRKREFwUVVRNkdPNy16N01DQ3k2bHVJbVNkLXdkcDhHY3pYY3c0ZkhKOW9Jblk3SlJGbU5XRGdJQzBIM2lGZldqeHp5SVhRclNzQ1BGY3dPMGRZZVRnYWdmZUYyVkdMeEZ5R3ZPbXhRdGR6a1BEeTk3dmhfaFFObGdzWFN3aDhMMzBiVWlWM242N2s?oc=5","date":"2025-05-12","type":"pipeline","source":"GlobeNewswire","summary":"Collegium Announces $25 Million Accelerated Share Repurchase Program - GlobeNewswire","headline":"Collegium Announces $25 Million Accelerated Share Repurchase Program","sentiment":"neutral"}],"patents":[{"drugName":"Xtampza ER","drugSlug":"oxycodone","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":143100000},{"drugName":"Tramadol ER","drugSlug":"tramadol","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":10300000}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Endo International","Purdue Pharma","Teva Pharmaceuticals"],"therapeuticFocus":["Pain Management"],"financials":{"source":"sec_edgar+yahoo","revenue":780567000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":780567000,"period":"2025-12-31"},{"value":205449000,"period":"2025-12-31"},{"value":209361000,"period":"2025-09-30"},{"value":188000000,"period":"2025-06-30"},{"value":177757000,"period":"2025-03-31"}],"grossProfit":463257000,"grossProfitHistory":[{"period":"2025-12-31","value":463257000},{"period":"2024-12-31","value":377344000},{"period":"2023-12-31","value":326169000},{"period":"2022-12-31","value":209488000}],"rdSpend":0,"rdSpendHistory":[{"period":"2024-12-31","value":0},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":3983000},{"period":"2021-12-31","value":9451000}],"sgaSpend":284803000,"operatingIncome":178454000,"operatingIncomeHistory":[{"period":"2025-12-31","value":178454000},{"period":"2024-12-31","value":166981000},{"period":"2023-12-31","value":166961000},{"period":"2022-12-31","value":33319000}],"netIncome":62870000,"netIncomeHistory":[{"period":"2025-12-31","value":62870000},{"period":"2024-12-31","value":69190000},{"period":"2023-12-31","value":48155000},{"period":"2022-12-31","value":-25002000}],"eps":1.73,"epsHistory":[{"period":"2025-12-31","value":1.73},{"period":"2024-12-31","value":1.86},{"period":"2023-12-31","value":1.29},{"period":"2022-12-31","value":-0.74}],"cash":231252000,"cashHistory":[{"period":"2025-12-31","value":231252000},{"period":"2024-12-31","value":70565000},{"period":"2023-12-31","value":238947000},{"period":"2022-12-31","value":173688000}],"totalAssets":1656834000,"totalLiabilities":1355159000,"totalDebt":814864000,"equity":301675000,"operatingCashflow":329323000,"operatingCashflowHistory":[{"period":"2025-12-31","value":329323000},{"period":"2024-12-31","value":204980000},{"period":"2023-12-31","value":274749000},{"period":"2022-12-31","value":124230000}],"capex":-1740000,"capexHistory":[{"period":"2025-12-31","value":-1740000},{"period":"2024-12-31","value":-1652000},{"period":"2023-12-31","value":-461000},{"period":"2022-12-31","value":-1622000}],"freeCashflow":327583000,"dividendsPaid":null,"buybacks":-25104000,"employees":423,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":67640000,"ebit":48328000,"ebitda":104724000,"period":"2025-12-31","revenue":205449000,"epsBasic":0.54,"netIncome":16963000,"rdExpense":null,"epsDiluted":0.46,"grossProfit":128378000,"operatingIncome":60738000},{"sga":67103000,"ebit":65203000,"ebitda":121709000,"period":"2025-09-30","revenue":209361000,"epsBasic":1,"netIncome":31507000,"rdExpense":null,"epsDiluted":0.84,"grossProfit":129171000,"operatingIncome":62068000},{"sga":73637000,"ebit":37488000,"ebitda":94096000,"period":"2025-06-30","revenue":188000000,"epsBasic":0.38,"netIncome":11983000,"rdExpense":null,"epsDiluted":0.34,"grossProfit":108384000,"operatingIncome":34747000},{"sga":76423000,"ebit":23912000,"ebitda":80476000,"period":"2025-03-31","revenue":177757000,"epsBasic":0.08,"netIncome":2417000,"rdExpense":null,"epsDiluted":0.07,"grossProfit":97324000,"operatingIncome":20901000},{"sga":63091000,"ebit":39923000,"ebitda":96435000,"period":"2024-12-31","revenue":181949000,"epsBasic":0.39,"netIncome":12536000,"rdExpense":null,"epsDiluted":0.36,"grossProfit":98288000,"operatingIncome":35197000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":35.13,"previousClose":34.87,"fiftyTwoWeekHigh":50.79,"fiftyTwoWeekLow":28.34,"fiftyTwoWeekRange":"28.339 - 50.787","fiftyDayAverage":34.69,"twoHundredDayAverage":39.57,"beta":0.76,"enterpriseValue":1638902912,"forwardPE":4.9,"priceToBook":3.64,"priceToSales":1.43,"enterpriseToRevenue":2.06,"enterpriseToEbitda":3.86,"pegRatio":0,"ebitda":425054016,"ebitdaMargin":53.4,"freeCashflow":332619008,"operatingCashflow":331038016,"totalDebt":929689984,"debtToEquity":297.6,"currentRatio":1.71,"returnOnAssets":7.6,"returnOnEquity":27.4,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":6,"targetMeanPrice":54.33,"targetHighPrice":60,"targetLowPrice":45,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.9,"institutionHeldPercent":120.6,"sharesOutstanding":32433779,"floatShares":32061764,"sharesShort":5936417,"shortRatio":11.76,"shortPercentOfFloat":18.3,"epsTrailing":2.06,"epsForward":7.11,"revenuePerShare":25.06,"bookValue":9.64,"officers":[{"age":50,"name":"Mr. Vikram  Karnani","title":"CEO, President & Director"},{"age":49,"name":"Ms. Colleen  Tupper","title":"Executive VP & CFO"},{"age":61,"name":"Mr. David  Dieter","title":"Executive VP, General Counsel & Corporate Secretary"},{"age":53,"name":"Mr. Scott  Dreyer","title":"Executive VP & Chief Commercial Officer"},{"age":64,"name":"Dr. Thomas B. Smith FAAFP, M.D.","title":"Executive VP & Chief Medical Officer"},{"age":null,"name":"Mr. Ian  Karp M.B.A.","title":"Head of Investor Relations"},{"age":null,"name":"Ms. Jessica  Cotrone","title":"Senior Vice President of Communications & Corporate Affairs"},{"age":null,"name":"Ms. Jane  Gonnerman","title":"Executive Vice President of Strategy & Corporate Development"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.collegiumpharma.com","phone":"781 713 3699"}}